Business
UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriers NEW YORK and SACRAMENTO,
About this update from Waldencast Plc
[{"type":"text","content":"Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriers\nNEW YORK and SACRAMENTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced that it has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi‘s Hyaluronic Acid (ALOHA) Program. Alpha was selected as an ALOHA launch partner for its demonstrated commitment to innovation, education, collaboration, and advancing aesthetic medicine through scalable, high-quality care models. Through this real-world evaluation collaboration, Alpha will conduct a structured, multi-site evaluation of Obagi® saypha® MagIQ™ across its network of practices. The program will leverage Alpha’s strengths in systematic education, patient satisfaction, and cross-practice culture to generate real-world evidence demonstrating the value of integrating Obagi’s first FDA-approved injectable hyaluronic acid filler into diverse clinical environments. “At Alpha, we’re focused on building capabilities and partnerships that meaningfully support our practices,” said John Wheeler, CEO of Alpha Aesthetics Partners. “What stood out about Obagi’s approach was the emphasis on real-world data and a thoughtful look at how skincare and injectables can work together to drive better outcomes for patients and providers.” The ALOHA Program is designed to evaluate both clinical performance and patient experience, while supporting providers with complete Obagi protocols aimed at deepening patient relationships and driving consistent, high-quality outcomes. Standardized data will be collected across participating Alpha practices, with initial findings scheduled to be presented at the upcoming Alpha Summit. Results will also be shared at key industry conferences to highlight the real-world impact of introducing a new injectable across a leading network of aesthetic practices. \"Partnering with an innovative leader like Alpha underscores Obagi’s commitment to launching new aesthetics solutions grounded in meaningful real-world evidence,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA collaboration with Alpha brings together strong clinical ...